^
Association details:
| Biomarker: | IGF1 rs2946834 |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Germline polymorphisms in genes involved in the IGF1-pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients
Excerpt:
In addition, wt KRAS patients harboring IGF1 rs2946834 A/A genotype had a 50% objective response rate compared with 0% for A/G genotype. These results indicate that IGF1 pathway polymorphisms are potential predictive/prognostic molecular markers for cetuximab efficacy in wt KRAS mCRC patients.
DOI:
10.1158/1078-0432.CCR-11-1115
